What Does The Negative FDA Review For Intercept’s OCA Hold For Other NASH Drugs?

 
• By Joseph Haas
  
Comparative analysis
Analysts saw FDA panel as bad news for FXR agonists, but not other NASH classes • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip